- Adjusted EPS: $5.37, up from $5.15 year over year, exceeding estimate of $5.12
- Revenue: $10.54 billion, down 1.4% year over year, but above estimate of $10.51 billion
- Life Sciences Revenue: $2.36 billion, down 4.4% year over year, estimate was $2.35 billion
- Analytical Instruments Revenue: $1.78 billion, up 1.9%, estimate was $1.75 billion
- Specialty Diagnostics Revenue: $1.12 billion, up 0.7%, estimate was $1.09 billion
- Lab Products & Services Revenue: $5.76 billion, down 1.3%, matches estimate of $5.76 billion
- Foreign Currency Impact: Sales decreased by 1%, estimate was a 0.6% decrease
- Adjusted Operating Income: $2.35 billion, down 1% year over year, estimate was $2.31 billion
- Adjusted Operating Margin: 22.3%, higher than last year’s 22.2% and the estimate of 22%
- Eliminations Revenue: -$470 million, a decline of 1.1% year over year, estimate was -$464.8 million
- Guidance: Thermo Fisher is increasing its full-year revenue and adjusted EPS guidance
- Analyst Ratings: 21 buys, 5 holds, no sells
Thermo Fisher Scientific Inc on Smartkarma
Analyst coverage of Thermo Fisher Scientific Inc on Smartkarma has been positive, with insights provided by Baptista Research. In their report titled “Thermo Fisher Scientific: What Is Their Long-Term Growth Strategy Towards Market Share Expansion? – Major Drivers,” Baptista Research highlights the company’s strong start to the year, with first-quarter revenue reaching $10.34 billion and a 2% increase in adjusted EPS. The report emphasizes Thermo Fisher Scientific’s robust financial performance driven by operational discipline, commercial execution, and an effective growth strategy. The raised guidance sets the stage for continued strong performance in 2024.
In another report by Baptista Research, titled “Thermo Fisher Scientific: 6 Major Factors Driving Its Growth In 2024! – Financial Forecasts,” the focus is on the company’s solid execution and operational discipline in 2023. With a revenue of $42.9 billion, adjusted operating income of $9.81 billion, and adjusted earnings per share of $21.55 in 2023, Thermo Fisher Scientific is credited for delivering short-term performance while enhancing its long-term competitive position. Analysts at Smartkarma are optimistic about the growth prospects of Thermo Fisher Scientific based on these reports.
A look at Thermo Fisher Scientific Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Thermo Fisher Scientific Inc, a company known for manufacturing scientific instruments and chemicals, has received a mix of Smart Scores across various categories. With a Value score of 2 and a Dividend score of 2, the company shows some room for improvement in terms of its perceived value and dividend offerings. However, Thermo Fisher Scientific Inc fares better in terms of Growth, Resilience, and Momentum, with scores of 3 in each category. This suggests that the company is showing promising signs of growth, resilience in the face of challenges, and positive momentum in the market.
Thermo Fisher Scientific Inc‘s overall outlook, based on the Smart Scores provided, indicates a moderately positive long-term trajectory. With a solid foundation in manufacturing scientific instruments and serving a wide range of institutions and agencies, the company’s growth potential, resilience, and market momentum bode well for its future prospects. Investors may find Thermo Fisher Scientific Inc to be a company with strong growth opportunities and a solid footing in the industry, despite some areas where improvements could be made in terms of value and dividend offerings.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
